|Bid||157.50 x 0|
|Ask||160.80 x 0|
|Day's range||157.89 - 184.08|
|52-week range||135.15 - 202.30|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||22.48|
|Forward dividend & yield||2.20 (1.48%)|
|Ex-dividend date||02 May 2023|
|1y target est||N/A|
Key Insights The projected fair value for Merck KGaA is €297 based on 2 Stage Free Cash Flow to Equity Current share...
Q3 2023 Exscientia PLC Earnings Call
FRANKFURT (Reuters) -Germany's diversified group Merck KGaA flagged that full-year operating earnings would likely be in the lower half of its target range on weak demand for specialty materials that are used to make biotech drugs and semiconductors. The maker of pharmaceuticals, lab gear and specialty chemicals confirmed that 2023 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, would come in between 5.8 billion euros ($6.21 billion) and 6.4 billion euros but would be "trending in the lower half of the absolute range". Last month, Merck raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.